These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 16007095

  • 1. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD.
    Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
    [Abstract] [Full Text] [Related]

  • 2. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.
    Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK.
    J Pharmacol Exp Ther; 2005 Feb; 312(2):718-25. PubMed ID: 15475592
    [Abstract] [Full Text] [Related]

  • 3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 4. PPARγ-induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent.
    Chraïbi A, Renauld S.
    Cell Physiol Biochem; 2014 Apr 14; 33(3):581-93. PubMed ID: 24603133
    [Abstract] [Full Text] [Related]

  • 5. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules.
    Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, Ronzaud C, Hummler E, Vallon V.
    Nephron; 2015 Apr 14; 129(1):68-74. PubMed ID: 25531136
    [Abstract] [Full Text] [Related]

  • 6. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 14; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 7. TZDs and diabetes: testing the waters.
    Semenkovich CF.
    Nat Med; 2005 Aug 14; 11(8):822-4. PubMed ID: 16079871
    [No Abstract] [Full Text] [Related]

  • 8. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling.
    Endo Y, Suzuki M, Yamada H, Horita S, Kunimi M, Yamazaki O, Shirai A, Nakamura M, Iso-O N, Li Y, Hara M, Tsukamoto K, Moriyama N, Kudo A, Kawakami H, Yamauchi T, Kubota N, Kadowaki T, Kume H, Enomoto Y, Homma Y, Seki G, Fujita T.
    Cell Metab; 2011 May 04; 13(5):550-61. PubMed ID: 21531337
    [Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
    Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A.
    Mol Pharmacol; 2009 Dec 04; 76(6):1333-40. PubMed ID: 19752200
    [Abstract] [Full Text] [Related]

  • 10. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J, Morales M, Caelles C.
    Diabetes; 2007 Jul 04; 56(7):1865-71. PubMed ID: 17416798
    [Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE.
    Clin Exp Pharmacol Physiol; 2009 May 04; 36(5-6):478-86. PubMed ID: 19673929
    [Abstract] [Full Text] [Related]

  • 12. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE, Hanna A.
    Diabetes Obes Metab; 2008 Apr 04; 10(4):312-28. PubMed ID: 18333890
    [Abstract] [Full Text] [Related]

  • 13. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM.
    Eur J Pharmacol; 2008 Oct 31; 596(1-3):173-9. PubMed ID: 18761337
    [Abstract] [Full Text] [Related]

  • 14. Hyperaldosteronemia and activation of the epithelial sodium channel are not required for sodium retention in puromycin-induced nephrosis.
    Lourdel S, Loffing J, Favre G, Paulais M, Nissant A, Fakitsas P, Créminon C, Féraille E, Verrey F, Teulon J, Doucet A, Deschênes G.
    J Am Soc Nephrol; 2005 Dec 31; 16(12):3642-50. PubMed ID: 16267158
    [Abstract] [Full Text] [Related]

  • 15. Fluid retention mediated by renal PPARgamma.
    Staels B.
    Cell Metab; 2005 Aug 31; 2(2):77-8. PubMed ID: 16098822
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.
    Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R.
    Am J Physiol Renal Physiol; 2012 Mar 01; 302(5):F540-51. PubMed ID: 22169011
    [Abstract] [Full Text] [Related]

  • 17. PPARgamma agonists, modulation of ion transporters, and fluid retention.
    Nofziger C, Blazer-Yost BL.
    J Am Soc Nephrol; 2009 Dec 01; 20(12):2481-3. PubMed ID: 19820124
    [No Abstract] [Full Text] [Related]

  • 18. Chronic lithium treatment inhibits amiloride-sensitive sodium transport in the rat distal nephron.
    Thomsen K, Bak M, Shirley DG.
    J Pharmacol Exp Ther; 1999 Apr 01; 289(1):443-7. PubMed ID: 10087036
    [Abstract] [Full Text] [Related]

  • 19. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
    Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T.
    Proc Natl Acad Sci U S A; 2005 Jun 28; 102(26):9406-11. PubMed ID: 15956187
    [Abstract] [Full Text] [Related]

  • 20. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
    Mall MA.
    Exp Physiol; 2009 Feb 28; 94(2):171-4. PubMed ID: 19060118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.